Exac Vitrakvi.

This week the FDA approved larotrectinib (aka Vitrakvi), marking the second approval ever with tissue agnosticism. Instead of microsatellite instability, this one’s for neurotrophic receptor tyrosine kinase (NTRK) gene fusions. Yes, NTRK fusions are hella less common but are no less important considering they’re usually found in diseases with no good alternative therapy such as salivary gland carcinomas and congenital sarcomas. | FDA 2018